Related references
Note: Only part of the references are listed.Recent advances in DDR (DNA damage response) inhibitors for cancer therapy
Binbin Cheng et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)
Structural insights into inhibitor regulation of the DNA repair protein DNA-PKcs
Shikang Liang et al.
NATURE (2022)
Small molecule DNA-PK inhibitors as potential cancer therapy: a patent review (2010-present)
Suwen Hu et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2021)
Genistein inhibits radiation-induced invasion and migration of glioblastoma cells by blocking the DNA-PKcs/Akt2/Rac1 signaling pathway
Xiongxiong Liu et al.
RADIOTHERAPY AND ONCOLOGY (2021)
GDC-0575, a CHK1 Inhibitor, Impairs the Development of Colitis and Colitis-Associated Cancer by Inhibiting CCR2+ Macrophage Infiltration in Mice
Min Li et al.
ONCOTARGETS AND THERAPY (2021)
BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies
Markus Berger et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Efficient Synthesis and Bioevaluation of Novel Dual Tubulin/Histone Deacetylase 3 Inhibitors as Potential Anticancer Agents
Xiaopeng Peng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Synthetic lethality as an engine for cancer drug target discovery
Alan Huang et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor
Frederick W. Goldberg et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Targeting DNA-PK in cancer
Giovanna Damia
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2020)
Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models
Frank T. Zenke et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Synthetic lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancer
Yunlong Hu et al.
CANCER SCIENCE (2020)
Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models
Ulrich Luecking et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment
Xiaopeng Peng et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Dual inhibition of DNA-PKcs and mTOR by CC-115 potently inhibits human renal cell carcinoma cell growth
Bing Zheng et al.
AGING-US (2020)
An Overview of HDAC Inhibitors and their Synthetic Routes
Xiaopeng Peng et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2019)
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity
Jacqueline H. L. Fok et al.
NATURE COMMUNICATIONS (2019)
The DNA-PK Inhibitor VX-984 Enhances the Radiosensitivity of Glioblastoma Cells Grown In Vitro and as Orthotopic Xenografts
Cindy R. Timme et al.
MOLECULAR CANCER THERAPEUTICS (2018)
SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules
Antoine Daina et al.
SCIENTIFIC REPORTS (2017)
Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions
Spyridon P. Basourakos et al.
CURRENT MEDICINAL CHEMISTRY (2017)
Targeting the DNA Damage Response in Cancer
Mark J. O'Connor
MOLECULAR CELL (2015)
DDR-mediated crosstalk between DNA-damaged cells and their microenvironment
Nicolas Malaquin et al.
FRONTIERS IN GENETICS (2015)
Beyond DNA Repair: DNA-PK Function in Cancer
Jonathan F. Goodwin et al.
CANCER DISCOVERY (2014)
Targeting the DNA damage response in oncology: past, present and future perspectives
Bristi Basu et al.
CURRENT OPINION IN ONCOLOGY (2012)
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies
Ting-Chao Chou
PHARMACOLOGICAL REVIEWS (2006)
The life and death of DNA-PK
SJ Collis et al.
ONCOGENE (2005)
Share Paper
